Sou Hu Cai Jing·2025-07-22 02:14Group 1 - The core viewpoint of the news highlights a positive market reaction to the National Medical Insurance Administration's meeting on supporting innovative drugs and medical devices, leading to a rise in the related stocks of innovative drug companies [1] - The Kexin Biopharmaceutical ETF (588250.SH) increased by 1.08%, with its associated index Kexin Biopharmaceutical (000683.SH) rising by 1.10%, indicating strong market performance [1] - Notable increases in major constituent stocks include: Borui Pharmaceutical up 5.91%, Junshi Biosciences-U up 4.04%, BeiGene-U up 1.74%, and Zai Lab-U up 1.87% [1] Group 2 - Southwest Securities emphasizes the accelerated revaluation of innovative drugs, maintaining a positive outlook on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces [2] - The life sciences sector is expected to continue expanding, with a strong push for domestic alternatives, exemplified by Aopumai's rapid expansion of its cell culture product pipeline, which has 258 drug research pipelines utilizing its products as of Q1 2025 [2] - CITIC Securities highlights the optimization of centralized procurement rules in the chemical pharmaceutical industry, promoting a shift towards quality competition, with a successful negotiation rate for innovative drugs exceeding 90% [2]